◼ Archived
Business
🔮 fades ✓
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie is expanding its immunology portfolio through a nearly $11 billion acquisition of Apogee Therapeutics.
Apogee Therapeutics
2 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Apogee Therapeutics
This hub groups 2 separate news trends connected to Apogee Therapeutics, spanning June 20, 2026 through June 22, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 18 article observations and 17 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
AbbVie is reportedly nearing an $11 billion acquisition of biotech firm Apogee Therapeutics to secure an experimental eczema treatment.